Companion Animals

Canine Myasthenia Gravis: Diagnosis and Management

Myasthenia gravis is an immune-mediated disorder disrupting nerve-muscle communication in dogs, causing progressive weakness and life-threatening complications if unmanaged.

Key Facts

MG occurs in acquired (immune-mediated) and congenital forms in dogs
Acetylcholine receptor antibody test confirms acquired MG in most cases
Megaesophagus affects up to 90% of MG dogs, causing regurgitation and aspiration risk
Thymoma underlies about 3-4% of acquired canine MG cases
Spontaneous remission occurs in approximately 50% of dogs within 6-18 months
Aspiration pneumonia is the leading cause of death in MG patients
Pyridostigmine improves neuromuscular transmission as primary treatment

Welfare Considerations

Dogs with myasthenia gravis experience significant functional impairment - weakness prevents normal movement, megaesophagus causes chronic regurgitation and pneumonia risk, and medication side effects add further burden. Careful nursing care including upright feeding positions (Bailey chairs), aspiration monitoring, and adjusted exercise are critical welfare interventions. Dogs achieving remission can return to near-normal quality of life.

What You Can Do

Use elevated feeding positions or Bailey chairs for MG dogs with megaesophagus
Monitor closely for respiratory distress indicating aspiration pneumonia
Follow prescribed pyridostigmine dosing carefully - overdose worsens weakness
Recheck acetylcholine receptor antibody titres to monitor remission progress
Ask your vet about thymoma screening via chest radiographs or CT
Provide padded, accessible resting areas for weak dogs
Join MG dog owner support communities for nursing care tips